The stock of Certara Inc. (NASDAQ:CERT) last traded at $16.06, down -2.37% from the previous session.
Data from the available sources indicates that Certara Inc. (NASDAQ:CERT) is covered by 9 analysts. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $26.00 and a low of $17.00, we find $20.00. Given the previous closing price of $16.45, this indicates a potential upside of 21.58 percent. CERT stock price is now 5.80% away from the 50-day moving average and -9.46% away from the 200-day moving average. The market capitalization of the company currently stands at $2.58B.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
In total, 2 analysts have assigned it a hold rating, and 6 have given it a buy rating. Brokers who have rated the stock have averaged $20.81 as their price target over the next twelve months.
With the price target enhanced from $17 to $19, Robert W. Baird Downgraded its rating from Outperform to Neutral for Certara Inc. (NASDAQ: CERT). On September 08, 2022, Berenberg recently initiated its ‘Buy’ rating on the stock quoting a target price of $23, while ‘Credit Suisse’ rates the stock as ‘Outperform’.
In other news, EQT Avatar Parent L.P., 10% Owner sold 29,954,521 shares of the company’s stock on Dec 08. The stock was sold for $449,317,815 at an average price of $15.00. Upon completion of the transaction, the 10% Owner now directly owns 0 shares in the company, valued at $0.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 22, PRESIDENT, SOFTWARE Pedersen Leif E sold 51,223 shares of the business’s stock. A total of $796,518 was realized by selling the stock at an average price of $15.55. This leaves the insider owning 175,500 shares of the company worth $2.82 million. Insiders disposed of 38,647,954 shares of company stock worth roughly $620.69 million over the past 1 year. A total of 1.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in CERT stock. A new stake in Certara Inc. shares was purchased by T. ROWE PRICE INVESTMENT MANAGEMENT, INC. during the first quarter worth $23,351,000. GENEVA CAPITAL MANAGEMENT LLC invested $18,795,000 in shares of CERT during the first quarter. In the first quarter, FIRST TRUST ADVISORS LP acquired a new stake in Certara Inc. valued at approximately $10,911,000. MARSHALL WACE, LLP acquired a new stake in CERT for approximately $10,212,000. CAAS CAPITAL MANAGEMENT LP purchased a new stake in CERT valued at around $8,643,000 in the second quarter. In total, there are 253 active investors with 87.40% ownership of the company’s stock.
With an opening price of $16.23 on Thursday morning, Certara Inc. (NASDAQ: CERT) set off the trading day. During the past 12 months, Certara Inc. has had a low of $10.60 and a high of $28.62. As of last week, the company has a debt-to-equity ratio of 0.28, a current ratio of 4.00, and a quick ratio of 4.00. The fifty day moving average price for CERT is $15.18 and a two-hundred day moving average price translates $17.74 for the stock.
The latest earnings results from Certara Inc. (NASDAQ: CERT) was released for Jun, 2022. According to the Health Information Services Company, earnings per share came in at $0.09, missing analysts’ expectations of $0.11 by -0.02. This compares to -$0.01 EPS in the same period last year. The net profit margin was -1.30% and return on equity was -0.40% for CERT. The company reported revenue of $84.7 million for the quarter, compared to $73.94 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 14.55 percent. For the current quarter, analysts expect CERT to generate $81.48M in revenue.
Certara Inc.(CERT) Company Profile
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers’ new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
